GlassScriptPhysician profile
Jeremy Chastain
NPI 1316200538
$4,699.22
in general payments reported to CMS, 2019-2025
12 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 88% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $182 · 2021: $550 · 2022: $31.30 · 2023: $23.27 · 2024: $180 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654 · Travel and Lodging: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.60 |
| Travel and Lodging | $1,350.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,037.91 | 2021-2025 | Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Boston Scientific Corporation | $1,265.37 | 2019-2025 | Intracept, Entrada |
| Stryker Corporation | $388.02 | 2021 | |
| Globus Medical, INC. | $328.92 | 2025 | Vyrsa V1 |
| Abbott Laboratories | $234.82 | 2022-2024 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $220.61 | 2020-2021 | |
| Averitas Pharma INC. | $117.59 | 2025 | Qutenza |
| Stimwave Technologies Incorporated | $25.99 | 2019-2020 | |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Glaxosmithkline, LLC. | $23.93 | 2025 | Nucala |
| Medtronic USA, INC. | $17.40 | 2019 | |
| Pfizer INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Chastain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.